ROBIN HOWARD W (President & CEO) received a stock award from NEKTAR THERAPEUTICS
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 12/23/2025ACC: 0001193125-25-331187
DirectorOfficer· President & CEO
Since Aug 2018
+108.33K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
108.33K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+21.67K
Price / share
—
Trade value
—
% of position
39.9%
12/22/2025
54.24K→75.91K
Total
Net shares
+21.67K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 12/22/2025 | A · Award | +21.67K | — | — | 39.9% | 54.24K | 75.91K |
| Total | +21.67K | $0.00 | ||||||
Derivative Transactions1
Stock Option
Direct
Converts to
Common Stock
86.67K shares
Shares
+86.67K
Strike price
43.48
Held after
86.67K
Exercisable
—
12/22/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option Direct | Common Stock86.67K shares | 12/22/2025 | A · Award | +86.67K | 43.48 | — | 86.67K |
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned28.00
Total
28.00 indirect28.00
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 28.00 | Indirect |
| Total | 28.00 | 28.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported